Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY4005130 versus placebo in adults with severe alopecia areata
NL-OMON61220Phase 2Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2026
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in alopecia areata comparing LY4005130 with Placebo (2 arms). Primary endpoint: Percentage of participants achieving absolute SALT score less than or equal to 20. Started Sep 2026; status: recruiting.
02
Drugs
LY4005130
03
Conditions
alopecia areata
Beyond the preview
Go deeper on NL-OMON61220.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61220.